170 related articles for article (PubMed ID: 35064066)
1. Oncotype DX Risk Recurrence Score and Total Mortality for Early-Stage Breast Cancer by Race/Ethnicity.
Moore J; Wang F; Pal T; Reid S; Cai H; Bailey CE; Zheng W; Lipworth L; Shu XO
Cancer Epidemiol Biomarkers Prev; 2022 Apr; 31(4):821-830. PubMed ID: 35064066
[TBL] [Abstract][Full Text] [Related]
2. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
[TBL] [Abstract][Full Text] [Related]
3. Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer-Specific Mortality Among US Women.
Hoskins KF; Danciu OC; Ko NY; Calip GS
JAMA Oncol; 2021 Mar; 7(3):370-378. PubMed ID: 33475714
[TBL] [Abstract][Full Text] [Related]
4. Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.
Roberts MC; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes KE; Carey LA; Troester MA; Wheeler SB
J Clin Oncol; 2016 Jan; 34(2):130-8. PubMed ID: 26598755
[TBL] [Abstract][Full Text] [Related]
5. Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia.
Collin LJ; Yan M; Jiang R; Ward KC; Crawford B; Torres MA; Gogineni K; Subhedar PD; Puvanesarajah S; Gaudet MM; McCullough LE
NPJ Breast Cancer; 2019; 5():32. PubMed ID: 31583272
[TBL] [Abstract][Full Text] [Related]
6. Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey.
Ünal Ç; Özmen T; Ordu Ç; Pilanci KN; İlgün AS; Gökmen E; Almuradova E; Özdoğan M; Güler N; Uras C; Kara H; Demircan O; Işık S; Alço G; Saip P; Aydın E; Duymaz T; Çelebi F; Yararbaş K; Soybir G; Ozmen V
Front Oncol; 2023; 13():1151733. PubMed ID: 37448522
[TBL] [Abstract][Full Text] [Related]
7. Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.
Berger NF; Zimmerman BS; Tharakan S; Suchman K; Cascetta KP; Blanter J; Moshier E; Ru M; Jaffer S; Tiersten A
Oncology; 2021; 99(11):699-702. PubMed ID: 34425579
[TBL] [Abstract][Full Text] [Related]
8. Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.
Zhang L; Hsieh MC; Petkov V; Yu Q; Chiu YW; Wu XC
Breast Cancer Res Treat; 2020 Apr; 180(2):491-501. PubMed ID: 32060781
[TBL] [Abstract][Full Text] [Related]
9. Reduction in Breast Cancer Death With Adjuvant Chemotherapy Among US Women According to Race, Ethnicity, and the 21-Gene Recurrence Score.
Huang HC; Calip GS; Weiss J; Simons Y; Gadi VK; Danciu OC; Rauscher GH; Hoskins KF
J Natl Compr Canc Netw; 2024 Jan; 22(1D):e237077. PubMed ID: 38190799
[TBL] [Abstract][Full Text] [Related]
10. Socioecologic Factors and Racial Differences in Breast Cancer Multigene Prognostic Scores in US Women.
Parab AZ; Kong A; Lee TA; Kim K; Nutescu EA; Malecki KC; Hoskins KF; Calip GS
JAMA Netw Open; 2024 Apr; 7(4):e244862. PubMed ID: 38568689
[TBL] [Abstract][Full Text] [Related]
11. Racial and Ethnic Disparities in Locoregional Recurrence Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer: A Post Hoc Analysis of the TAILORx Randomized Clinical Trial.
Kantor O; King TA; Freedman RA; Mayer EL; Chavez-MacGregor M; Korde LA; Sparano JA; Mittendorf EA
JAMA Surg; 2023 Jun; 158(6):583-591. PubMed ID: 37043210
[TBL] [Abstract][Full Text] [Related]
12. Correlation Between Oncotype DX, PREDICT and the Nottingham Prognostic Index: Implications for the Management of Early Breast Cancer.
Hillyar C; Rizki H; Abbassi O; Miles-Dua S; Clayton G; Gandamihardja T; Smith S
Cureus; 2020 Apr; 12(4):e7552. PubMed ID: 32382456
[TBL] [Abstract][Full Text] [Related]
13. Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer.
Han Y; Miao ZF; Lian M; Peterson LL; Colditz GA; Liu Y
Breast Cancer Res Treat; 2020 Dec; 184(3):915-925. PubMed ID: 32929567
[TBL] [Abstract][Full Text] [Related]
14. Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States From 2010 to 2015.
Kong X; Liu Z; Cheng R; Sun L; Huang S; Fang Y; Wang J
JAMA Netw Open; 2020 Oct; 3(10):e2020303. PubMed ID: 33074325
[TBL] [Abstract][Full Text] [Related]
15. Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study.
Davis BA; Aminawung JA; Abu-Khalaf MM; Evans SB; Su K; Mehta R; Wang SY; Gross CP
J Natl Compr Canc Netw; 2017 Mar; 15(3):346-354. PubMed ID: 28275035
[No Abstract] [Full Text] [Related]
16. Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial.
Albain KS; Gray RJ; Makower DF; Faghih A; Hayes DF; Geyer CE; Dees EC; Goetz MP; Olson JA; Lively T; Badve SS; Saphner TJ; Wagner LI; Whelan TJ; Ellis MJ; Wood WC; Keane MM; Gomez HL; Reddy PS; Goggins TF; Mayer IA; Brufsky AM; Toppmeyer DL; Kaklamani VG; Berenberg JL; Abrams J; Sledge GW; Sparano JA
J Natl Cancer Inst; 2021 Apr; 113(4):390-399. PubMed ID: 32986828
[TBL] [Abstract][Full Text] [Related]
17. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
[TBL] [Abstract][Full Text] [Related]
18. The Relationship of Race, Oncotype DX, and Ki67 in a Population Highly Screened For Breast Cancer.
Guth AA; Chun Kim J; Schwartz S; Montes J; Snyder RA; Axelrod D; Schnabel F
Breast J; 2017 Mar; 23(2):177-181. PubMed ID: 28299888
[TBL] [Abstract][Full Text] [Related]
19. Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
Glasgow A; Sechrist H; Bomeisl P; Gilmore H; Harbhajanka A
Breast Cancer; 2021 Mar; 28(2):321-328. PubMed ID: 32951186
[TBL] [Abstract][Full Text] [Related]
20. Understanding Racial and Ethnic Inequities in Uptake and Outcomes Following Multigene Prognostic Testing in Early Breast Cancer: The Promise of Real-World Data.
Wang X; Cho-Phan CD; Hoskins KF; Calip GS
Cancer Epidemiol Biomarkers Prev; 2022 Apr; 31(4):704-706. PubMed ID: 35373264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
